Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Dr. Ariz Sheikh - By following these strategies, you can better manage morning stiffness and improve your comfort and ...

Tilt is a new makeup brand with products designed to make beauty accessible to everyone. It’s the first beauty brand and ...

Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,400 shares, a ...

Positive association seen between osteoarthritis and OAB, but not for rheumatoid arthritis or psoriatic arthritis ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.